Eugen Tcaciuc

Prof. Eugen Tcaciuc


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021
Verified
Journal Article
Open access
ETEugen Tcaciuc
Eugen Tcaciuc
MPMariana Podurean
Mariana Podurean
ATAngela Tcaciuc
Angela Tcaciuc
Crigler-Najjar syndrome is a rare autosomal recessive inherited non-hemolytic unconjugated hyperbilirubinemia caused by UDP-glucuronosyltransferase deficiency. There are two forms of this disorder. Type 1 disease is associated with severe jaundice and neurologic impairment due to bilirubin encephalopathy that can result in permanent neurologic sequelae. Type 2 disease is associated with a lower serum bilirubin concentration and affected patients survive into adulthood without neurologic impairment. Currently, liver transplantation is the only available therapeutic method for these patients. Developing new curative approaches is a clinical need.

11 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
COCatalina Olaru-Stavila
Catalina Olaru-Stavila
SSSara Martina Steinmann
Sara Martina Steinmann
PMPatricia Mester
Patricia Mester
MMMartina Müller-Schilling
Martina Müller-Schilling
ETEugen Tcaciuc
Eugen Tcaciuc
KGKarsten Gülow
Karsten Gülow
The gastrointestinal (GI) barrier is a highly coordinated, multilayered defence system that maintains intestinal homeostasis by separating the luminal microbiota from the internal milieu. In liver cirrhosis, this barrier undergoes profound structural and functional disruption, emerging as a central driver of bacterial translocation and infection-related complications. Among these, spontaneous bacterial peritonitis (SBP) represents a major determinant of morbidity, mortality, and disease progression. Barrier failure in cirrhosis is not attributable to a single defect but results from the convergence of multiple interconnected mechanisms. Structural alterations include disruption of epithelial tight junctions and deterioration of the mucus layer, leading to increased intestinal permeability and loss of spatial compartmentalisation. These changes are compounded by microbial dysbiosis, characterised by reduced diversity, depletion of short-chain fatty acid-producing taxa, and expansion of pathobionts. In parallel, cirrhosis-associated immune dysfunction impairs both mucosal and systemic antimicrobial defences, while gut–vascular barrier disruption facilitates systemic dissemination of bacteria and microbial products. The resulting increase in bacterial translocation plays a pivotal role in the pathogenesis of SBP and contributes to systemic inflammation, circulatory dysfunction, and acute decompensation. Importantly, this process establishes a self-amplifying pathogenic loop in which barrier dysfunction, dysbiosis, and immune dysregulation mutually reinforce each other. Recent advances have identified key molecular pathways involved in barrier regulation, including bile acid–FXR signalling and microbiome-derived metabolites, providing novel targets for therapeutic intervention. While current management relies largely on antibiotics and supportive care, emerging strategies aim to restore barrier integrity and modulate the gut–liver axis. A deeper understanding of GI barrier dysfunction offers new opportunities to prevent bacterial translocation and improve clinical outcomes in patients with liver cirrhosis.

Verified
Journal Article
Open access
PDF file
AVAlexandru Văcariu
Alexandru Văcariu
SISilvia Mihaela Ilie
Silvia Mihaela Ilie
CVCristin Constantin Vere
Cristin Constantin Vere
Adina Turcu-StiolicaAdina Turcu-Stiolica
Adina Turcu-Stiolica
EMEleni Manthopoulou
Eleni Manthopoulou
Bogdan Silviu UngureanuBogdan Silviu Ungureanu
Bogdan Silviu Ungureanu
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal solid malignancies, and reliable prognostic biomarkers are urgently needed to guide risk stratification and treatment. CD74 has been implicated in tumor progression, invasion, and pro-inflammatory signaling in various cancers. This systematic review and meta-analysis aimed to evaluate the association between CD74 expression and key clinicopathological features and survival outcomes in patients with PDAC. A systematic literature search was conducted in PubMed, Web of Science, and Scopus to identify eligible studies reporting on CD74 expression in PDAC tissues (PROSPERO: CRD420261402709). Studies were selected following the PRISMA 2020 guidelines. The methodological quality of the included studies was assessed using the QUIPS tool. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for the associations between CD74 expression and perineural invasion (PNI), lymphatic invasion, lymph node metastasis (pN), vascular permeation, pTNM stage, and overall survival. Statistical analyses were performed using Review Manager v5.4. DerSimonian–Laird random-effects models were applied as sensitivity analysis for every outcome, with Mantel–Haenszel fixed-effects models as the primary analysis according to the level of heterogeneity, which was quantified using the I2 statistic. A total of 83 records were initially identified, of which five studies met the inclusion criteria and were included in the quantitative synthesis. CD74-positive expression was significantly associated with an increased risk of perineural invasion (four cohorts, 351 patients; OR = 3.69; 95% CI: 2.27–5.99; p < 0.00001; I2 = 0%), lymphatic invasion (four cohorts, 351 patients; OR = 2.05; 95% CI: 1.21–3.46; p = 0.007; I2 = 0%), and lymph node metastasis (four cohorts, 462 patients; OR = 1.94; 95% CI: 1.27–2.96; p = 0.002; I2 = 0%). A non-significant trend toward increased vascular permeation (three cohorts, 181 patients; OR = 1.99; 95% CI: 0.84–4.68; p = 0.12; I2 = 0%) and advanced pTNM stage (three cohorts, 284 patients; OR = 1.62; 95% CI: 0.93–2.82; p = 0.09; I2 = 0%) was also observed. Importantly, CD74 positivity was significantly associated with worse overall survival (three cohorts, 293 patients; HR = 2.04, 95% CI: 1.45–2.88; p < 0.00001; I2 = 0%). This analysis was structured into two subgroups: HR = 2.21 (95% CI: 1.50–3.25) in the two cohorts contributing multivariable-adjusted, immunohistochemistry-based estimates, and HR = 1.52 (95% CI: 0.72–3.21) in the single cohort contributing a univariable estimate reconstructed from transcript-level data, with no significant difference between the subgroups (p = 0.38). Because the estimated between-study variance was zero for every outcome, random-effects estimates were almost identical to the fixed-effects estimates throughout. As the pooled survival estimate combines adjusted with unadjusted estimates, it describes a prognostic association rather than established independent prognostic value. This meta-analysis demonstrates that elevated CD74 expression in PDAC is significantly associated with perineural invasion, lymphatic invasion, lymph node metastasis, and poorer overall survival, supporting an association with an adverse prognostic. Because the evidence base comprises few retrospective cohorts that used different, non-standardized thresholds to define CD74 positivity and different definitions of several outcomes, these findings should be regarded as hypothesis-generating: they identify CD74 as a candidate for prospective validation and mechanistic investigation rather than as an established biomarker for risk stratification or therapeutic decision-making. Further large-scale prospective studies are warranted to validate these results and explore the clinical utility of CD74-targeted strategies.